MCID: MYS005
MIFTS: 63

Myositis

Categories: Rare diseases, Neuronal diseases, Infectious diseases, Genetic diseases, Muscle diseases

Aliases & Classifications for Myositis

MalaCards integrated aliases for Myositis:

Name: Myositis 53 12 72 28 51 40 41 14 69
Myopathy, Familial Idiopathic Inflammatory; Iim 53
Myopathy, Familial Idiopathic Inflammatory 53
Inflammatory Disorder of Muscle 12
Iim 53

Characteristics:

OMIM:

53
Inheritance:
autosomal dominant


HPO:

31
myositis:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 53 160750
Disease Ontology 12 DOID:633
MeSH 41 D009220
NCIt 46 C27578
MedGen 39 C0027121
SNOMED-CT via HPO 65 263681008 249939004
UMLS 69 C0027121

Summaries for Myositis

MedlinePlus : 40 Myositis means inflammation of the muscles that you use to move your body. An injury, infection, or autoimmune disease can cause it. Two specific kinds are polymyositis and dermatomyositis. Polymyositis causes muscle weakness, usually in the muscles closest to the trunk of your body. Dermatomyositis causes muscle weakness, plus a skin rash. Other symptoms of myositis may include Fatigue after walking or standing Tripping or falling Trouble swallowing or breathing Doctors may use a physical exam, lab tests, imaging tests and a muscle biopsy to diagnose myositis. There is no cure for these diseases, but you can treat the symptoms. Polymyositis and dermatomyositis are first treated with high doses of a corticosteroid. Other options include medications, physical therapy, exercise, heat therapy, assistive devices, and rest. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Myositis, also known as myopathy, familial idiopathic inflammatory; iim, is related to granulomatous myositis and inclusion body myositis, and has symptoms including proximal muscle weakness, myalgia and muscle weakness. An important gene associated with Myositis is IFIH1 (Interferon Induced With Helicase C Domain 1), and among its related pathways/superpathways are tRNA Aminoacylation and Alzheimers Disease Pathway. The drugs Simvastatin and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include bone, testes and skin, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A myopathy characterized by muscle inflammation.

Wikipedia : 72 Myositis is inflammation or swelling of the muscles. Injury, medicines, infection, or an immune disorder... more...

Description from OMIM: 160750

Related Diseases for Myositis

Diseases in the Myositis family:

Bacterial Myositis Viral Myositis

Diseases related to Myositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 416)
# Related Disease Score Top Affiliating Genes
1 granulomatous myositis 33.4 NCAM1 PIK3C2A TTN
2 inclusion body myositis 33.3 APP BACE1 BACE2 DYSF GNE MSTN
3 antisynthetase syndrome 32.4 HARS TARS
4 dermatomyositis 32.2 AARS CHKB HARS IFIH1 PIK3C2A TARS
5 polymyositis 31.9 AARS CHKB HARS MB PIK3C2A
6 metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration 30.2 CHKB MB PIK3C2A
7 polyglucosan body myopathy 1 with or without immunodeficiency 30.2 CAPN3 DMD
8 myopathy 30.1 CAPN3 CHKB DMD DYSF GNE MB
9 compartment syndrome 30.0 CHKB MB PIK3C2A
10 muscular dystrophy, limb-girdle, type 2a 29.9 CAPN3 DMD DYSF TTN
11 anterior compartment syndrome 29.9 DYSF PIK3C2A
12 localized lipodystrophy 29.9 DMD DYSF
13 muscular dystrophy-dystroglycanopathy , type c, 5 29.8 CAPN3 DYSF TTN
14 limb-girdle muscular dystrophy 29.8 CAPN3 DMD DYSF TTN
15 myotonia 29.8 CHKB DMD MSTN
16 muscular dystrophy 29.8 CAPN3 DMD DYSF TTN
17 neuromuscular disease 29.4 DMD GNE TTN
18 gas gangrene 29.3 DMD MYOD1 PIK3C2A
19 muscular dystrophy, duchenne type 28.7 DMD MB MSTN MYOD1 PIK3C2A TTN
20 myositis ossificans 12.3
21 focal myositis 12.2
22 myositis fibrosa 12.2
23 fibrodysplasia ossificans progressiva 12.2
24 congenital disorder of glycosylation, type iim 12.1
25 bacterial myositis 12.1
26 viral myositis 12.1
27 infective myositis 12.1
28 fungal myositis 12.1
29 idiopathic eosinophilic myositis 12.1
30 overlap myositis 12.0
31 pyomyositis 11.9
32 juvenile overlap myositis 11.9
33 idiopathic inflammatory myopathy 11.8
34 slc35a2-cdg 11.3
35 welander distal myopathy, swedish type 11.2
36 childhood type dermatomyositis 11.2
37 orbital plasma cell granuloma 11.0
38 necrotizing autoimmune myopathy 11.0
39 xanthinuria, type ii 10.9
40 muscle disorders 10.9
41 foot drop 10.9
42 osseous heteroplasia, progressive 10.8
43 epidemic pleurodynia 10.8
44 autosomal recessive limb-girdle muscular dystrophy type 2f 10.5 CAPN3 DYSF
45 muscular dystrophy, limb-girdle, type 2j 10.5 CAPN3 TTN
46 cardioneuromyopathy with hyaline masses and nemaline rods 10.5 DMD TTN
47 autosomal recessive limb-girdle muscular dystrophy type 2h 10.5 CAPN3 DYSF
48 isolated hyperckemia 10.5 CAPN3 DMD
49 muscular dystrophy, limb-girdle, type 1c 10.5 DYSF MSTN
50 muscular dystrophy, limb-girdle, type 2h 10.5 CAPN3 DYSF TTN

Graphical network of the top 20 diseases related to Myositis:



Diseases related to Myositis

Symptoms & Phenotypes for Myositis

Symptoms via clinical synopsis from OMIM:

53
Muscle:
proximal muscle weakness
myositis


Clinical features from OMIM:

160750

Human phenotypes related to Myositis:

31
# Description HPO Frequency HPO Source Accession
1 myositis 31 HP:0100614
2 proximal muscle weakness 31 HP:0003701

UMLS symptoms related to Myositis:


myalgia, muscle weakness, torticollis, sciatica, myoclonus, muscle spasticity, muscle rigidity, muscle cramp, back pain

GenomeRNAi Phenotypes related to Myositis according to GeneCards Suite gene sharing:

25 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.66 PIK3C2A
2 Decreased viability GR00221-A-1 9.66 CHKB GNE PIK3C2A
3 Decreased viability GR00221-A-2 9.66 CHKB PIK3C2A TTN
4 Decreased viability GR00221-A-3 9.66 CHKB GNE
5 Decreased viability GR00221-A-4 9.66 CHKB DYSF GNE PIK3C2A TTN
6 Decreased viability GR00240-S-1 9.66 PIK3C2A
7 Decreased viability GR00301-A 9.66 CHKB DYSF
8 Decreased viability GR00342-S-1 9.66 PIK3C2A TTN
9 Decreased viability GR00342-S-2 9.66 PIK3C2A
10 Decreased viability GR00342-S-3 9.66 TTN PIK3C2A
11 Decreased hepcidin::fluc mRNA expression GR00253-A 9.61 APP BACE1 DMD DYSF MSTN NARS

MGI Mouse Phenotypes related to Myositis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.17 PIK3C2A TTN AARS APP BACE1 CHKB
2 growth/size/body region MP:0005378 10.13 AARS APP BACE1 BACE2 CAPN3 DMD
3 cellular MP:0005384 10.11 AARS APP BACE1 BACE2 DMD IFIH1
4 cardiovascular system MP:0005385 10.1 AARS APP CAPN3 DMD GNE MB
5 homeostasis/metabolism MP:0005376 10.07 APP BACE1 CAPN3 CHKB DMD DYSF
6 mortality/aging MP:0010768 10 FBL GNE IFIH1 MB MSTN MYOD1
7 muscle MP:0005369 9.73 APP BACE1 CAPN3 CHKB DMD DYSF
8 no phenotypic analysis MP:0003012 9.17 APP BACE1 CAPN3 DMD DYSF MSTN

Drugs & Therapeutics for Myositis

Drugs for Myositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 171)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 2,Phase 3 79902-63-9 54454
2
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3 1994-09-7, 94-09-7 2337
3
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
4
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
5
Abatacept Approved Phase 4,Phase 3,Phase 2 332348-12-6 10237
6
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
7
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
8
Liraglutide Approved Phase 4 204656-20-2 44147092
9
Pirfenidone Approved, Investigational Phase 4 53179-13-8 40632
10 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3
11
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 3 303-98-0 5281915
12 Anticholesteremic Agents Phase 4,Phase 2,Phase 3
13 Antimetabolites Phase 4,Phase 3,Phase 2
14 Calcium, Dietary Phase 4,Phase 3,Phase 2,Early Phase 1
15 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 2,Phase 3
16 Hypolipidemic Agents Phase 4,Phase 2,Phase 3
17 Lipid Regulating Agents Phase 4,Phase 2,Phase 3
18 Rosuvastatin Calcium Phase 4 147098-20-2
19 Anti-HIV Agents Phase 4
20 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Anti-Retroviral Agents Phase 4
22 Antiviral Agents Phase 4,Phase 1
23 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
24 Reverse Transcriptase Inhibitors Phase 4
25
Tenofovir Phase 4 147127-20-6 464205
26 Vaccines Phase 4
27 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Adrenocorticotropic Hormone Phase 4,Phase 2
30 beta-endorphin Phase 4,Phase 2
31 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
32 Hormones Phase 4,Phase 3,Phase 2,Phase 1
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
34 Melanocyte-Stimulating Hormones Phase 4,Phase 2
35 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Angiotensin II Type 1 Receptor Blockers Phase 4
38 Angiotensin Receptor Antagonists Phase 4
39 Angiotensinogen Phase 4
40 Antihypertensive Agents Phase 4
41 HIV Protease Inhibitors Phase 4
42
Olmesartan medoxomil Phase 4 144689-63-4 130881
43
protease inhibitors Phase 4
44 Serine Proteinase Inhibitors Phase 4
45 Vasoconstrictor Agents Phase 4
46 Micronutrients Phase 4,Phase 2,Phase 3
47 Trace Elements Phase 4,Phase 2,Phase 3
48 Ubiquinone Phase 4,Phase 2,Phase 3
49 Vitamins Phase 4,Phase 2,Phase 3
50 insulin Phase 4,Phase 1

Interventional clinical trials:

(show top 50) (show all 167)

# Name Status NCT ID Phase Drugs
1 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
2 Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
3 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
4 Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being Completed NCT02255682 Phase 4 Simvastatin
5 Angiotensin II Blockade and Inflammation in Obesity Completed NCT01684748 Phase 4 Olmesartan medoxomil
6 Stop Atherosclerosis in Native Diabetics Study Completed NCT00147251 Phase 4 FDA approved drugs to treat blood pressure and cholesterol
7 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
8 Abatacept in Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
9 Living With Statins - Interventional Exercise Study Recruiting NCT02796378 Phase 4 Training+Simvastatin+Q10-placebo;Training+Simvastatin-placebo+Q10-placebo;Training+Simvastatin+Q10
10 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4 H.P. Acthar Gel
11 The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans Active, not recruiting NCT02403284 Phase 4 Liraglutide;Sugar Pill
12 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Not yet recruiting NCT02821689 Phase 4 Pirfenidone
13 Is Myopathy Part of Statin Therapy (IMPOSTER-16) Terminated NCT00127335 Phase 4 cellulose placebo vs. atorvastatin
14 Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis Unknown status NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
15 Arimoclomol in Sporadic Inclusion Body Myositis Completed NCT00769860 Phase 2, Phase 3 Arimoclomol
16 Treatment With TNF Blockade, Infliximab, in Patients With Myositis Completed NCT00443222 Phase 2, Phase 3 Infliximab
17 An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203 Completed NCT02573467 Phase 3 Bimagrumab;Placebo
18 Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT02250443 Phase 2, Phase 3 BYM338 (Bimagrumab)
19 Anakinra in Myositis Completed NCT01165008 Phase 2, Phase 3 Anakinra
20 Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients Completed NCT01925209 Phase 2, Phase 3 BYM338/bimagrumab;Placebo
21 Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus Completed NCT00504348 Phase 2, Phase 3 Tacrolimus
22 Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM Completed NCT00651040 Phase 3 Prednisone;Methotrexate
23 Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms Completed NCT01032993 Phase 2, Phase 3
24 High Dose Cyclophosphamide for Treatment of Scleroderma Completed NCT00501995 Phase 3 IV Cyclophosphamide
25 Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients Completed NCT00975000 Phase 3 Cinacalcet;Placebo
26 Scleroderma: Cyclophosphamide or Transplantation (SCOT) Completed NCT00114530 Phase 2, Phase 3 cyclophosphamide
27 Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome Completed NCT00025818 Phase 3 Ophthalmic Emulsion
28 Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM) Completed NCT00335985 Phase 3 GB-0998;Placebo of GB-0998
29 Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
30 Belimumab in Myositis Recruiting NCT02347891 Phase 2, Phase 3 Belimumab;Placebo
31 Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy Recruiting NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
32 Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) Recruiting NCT02728752 Phase 3 Octagam 10%
33 An Efficacy and Safety Study of Palovarotene for the Treatment of FOP Recruiting NCT03312634 Phase 3 Palovarotene
34 Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD Recruiting NCT01862926 Phase 2, Phase 3 Rituximab;Cyclophosphamide
35 Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis Active, not recruiting NCT02481453 Phase 2, Phase 3 Rapamycin;Placebo
36 Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis Terminated NCT00035958 Phase 2, Phase 3 Prednisone;Methotrexate;Etanercept
37 Statins for the Early Treatment of Sepsis Unknown status NCT00528580 Phase 2 Simvastatin;Identical-appearing placebo
38 Abatacept Treatment in Polymyositis and Dermatomyositis Unknown status NCT01315938 Phase 2 Abatacept;Abatacept
39 Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT01423110 Phase 2
40 Alemtuzumab to Treat Sporadic Inclusion Body Myositis Completed NCT00079768 Phase 2 Alemtuzumab (Campath)
41 Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis Completed NCT00774462 Phase 2 Rituximab
42 Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies Completed NCT00001261 Phase 2 Gamma Globulin
43 A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis Completed NCT00979654 Phase 2 Sifalimumab
44 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) Completed NCT00106184 Phase 2 Rituximab;Placebo
45 The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers Completed NCT00805870 Phase 2 Lovaza (omega-3-acid ethyl esters);Wheat Germ Oil
46 An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects Completed NCT02190747 Phase 2 Palovarotene;Placebo
47 Methimazole to Treat Polymyositis and Dermatomyositis Completed NCT00001421 Phase 2 methimazole
48 Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis Completed NCT00033891 Phase 2 Infliximab
49 Acthar in Treatment of Refractory Dermatomyositis and Polymyositis Completed NCT01906372 Phase 2 Adrenocorticotropic Hormone Gel
50 Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis Completed NCT00005571 Phase 2 h5G1.1-mAb

Search NIH Clinical Center for Myositis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: myositis

Genetic Tests for Myositis

Genetic tests related to Myositis:

# Genetic test Affiliating Genes
1 Myositis 28

Anatomical Context for Myositis

MalaCards organs/tissues related to Myositis:

38
Bone, Testes, Skin, Lung, T Cells, Skeletal Muscle, Tongue

Publications for Myositis

Articles related to Myositis:

(show top 50) (show all 1995)
# Title Authors Year
1
Response to: 'Detection of myositis-specific antibodies' by Vulsteke<i>et al</i>. ( 29382639 )
2018
2
Myositis following spine radiosurgery for metastatic disease: a case series. ( 29372858 )
2018
3
Detection of myositis-specific antibodies: additional notes. ( 29444906 )
2018
4
Orbital Myositis: An Underrecognized Clinical Syndrome with a Need of Management Guidelines. ( 29334042 )
2018
5
Prevalence and predictors of asymptomatic vertebral fractures in inflammatory myositis. ( 29314651 )
2018
6
6"-<sup>18</sup>F-Fluoromaltotriose PET Evaluation in Escherichia-Coli-Induced Myositis: is there Uptake Saturation in Control? ( 29449448 )
2018
7
Detection of myositis-specific antibodies. ( 29371203 )
2018
8
Inclusion body myositis and human immunodeficiency virus type 1: A new case report and literature review. ( 29426734 )
2018
9
Eosinophilic Esophageal Myositis a Plausible Cause of Histological Changes of Primary Jackhammer Esophagus: A Case Report. ( 29311727 )
2018
10
Causation of Acute Flaccid Paralysis by Myelitis and Myositis in Enterovirus-D68 Infected Mice Deficient in Interferon I+I^/I^ Receptor Deficient Mice. ( 29329211 )
2018
11
Diffusion weighted MRI in myositis - the value of ADC histogram analysis. ( 29436842 )
2018
12
Effect of butylphthalide intervention on experimental autoimmune myositis in guinea pigs. ( 29387187 )
2018
13
Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis. ( 29363513 )
2018
14
Purulent myositis of the thigh as a presentation of perforated low rectal cancer. ( 29364005 )
2018
15
Paratesticular myositis ossificans of the spermatic cord. ( 29301813 )
2018
16
Nocardiosis incognito: Primary cutaneous nocardiosis with extension to myositis and pleural infection. ( 29296648 )
2018
17
Focal myositis diffusely involving multiple masticatory muscles. ( 29400113 )
2018
18
Analysis of Clinical Manifestations and Laboratory Findings in Children with Influenza B-Associated Myositis: A Single Center Study. ( 29383210 )
2018
19
Immune and myodegenerative pathomechanisms in inclusion body myositis. ( 28589170 )
2017
20
Cytokine Profiling of Serum Allows Monitoring of Disease Progression in Inclusion Body Myositis. ( 29172005 )
2017
21
Benign Acute Childhood Myositis During Influenza B Outbreak. ( 28795360 )
2017
22
Extraskeletal osteosarcoma arising in myositis ossificans: a case report and review of the literature. ( 28536749 )
2017
23
Giant cell myocarditis masquerading as orbital myositis with a rapid, fulminant course necessitating mechanical support and heart transplantation. ( 28772042 )
2017
24
Henoch-SchAPnlein Purpura With Muscle Involvement, Presenting as Myositis. ( 28002161 )
2017
25
The EuroMyositis registry: an international collaborative tool to facilitate myositis research. ( 28855174 )
2017
26
Rare case of herpes zoster ophthalmicus with orbital myositis, oculomotor nerve palsy and anterior uveitis. ( 28195080 )
2017
27
Myositis-associated usual interstitial pneumonia has a better survival than idiopathic pulmonary fibrosis. ( 28082622 )
2017
28
Concomitant occurrence of FXTAS and clinically defined sporadic inclusion body myositis: report of two cases. ( 28857524 )
2017
29
Non-granulomatous myositis in a patient with ulcerative colitis who showed symptoms resembling gastrocnemius myalgia syndrome. ( 28132973 )
2017
30
A 64-year-old woman with interstitial lung disease and positive antibodies against aminoacyl-transfer RNA synthetases in the absence of myositis: presentation of an anti-PL-12 positive antisynthetase syndrome. ( 29173135 )
2017
31
Myositis ossificans in elbow mimicking soft tissue sarcoma: Similar clinical and radiological findings. ( 28641932 )
2017
32
Fist sign in inclusion body myositis. ( 28215761 )
2017
33
A Systematic Review and Meta-Analysis ofA Prevalence Studies of Sporadic Inclusion Body Myositis. ( 28505979 )
2017
34
Unsupervised Exercise-Induced Myositis Ossificans in the Brachialis Muscle of a Young Healthy Male: A Case Report. ( 28795074 )
2017
35
Proliferative myositis of the latissimus dorsi presenting in a 20-year-old male athlete. ( 29341517 )
2017
36
Which nonautoimmune myopathies are most frequently misdiagnosed as myositis? ( 28832350 )
2017
37
Unfounded Claims of Improved Functional Outcomes Attributed to Follistatin Gene Therapy in Inclusion Body Myositis. ( 28927986 )
2017
38
Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients. ( 28076913 )
2017
39
Sarcoidosis: Is It a Possible Trigger of Inclusion Body Myositis? ( 28523201 )
2017
40
Ultrasound for the rheumatologist - focal myositis. ( 29231909 )
2017
41
Botulinum toxin alleviates dysphagia of patients with inclusion body myositis. ( 28870555 )
2017
42
Imaging in myositis ossificans: Bone scintigraphy and 18F-fluorodeoxyglucose positron emission tomography/computed tomography. ( 28325501 )
2017
43
Apparent diffusion coefficient (ADC) does not correlate with different serological parameters in myositis and myopathy. ( 28899124 )
2017
44
Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients. ( 28283597 )
2017
45
A case of inclusion body myositis complicated by microscopic polyangiitis. ( 28726537 )
2017
46
Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. ( 28821685 )
2017
47
Investigating Idiopathic Inflammatory Myopathy; Initial Cross Speciality Experience with Use of the Extended Myositis Antibody Panel. ( 28567235 )
2017
48
Disseminated<i>Pasteurella multocida</i>infection: Cellulitis, osteomyelitis, and myositis. ( 28966913 )
2017
49
Clinical Implications and Hospital Outcome of Immune-Mediated Myositis in Horses. ( 28044365 )
2017
50
A Case of Asymptomatic Inclusion Body Myositis. ( 28221303 )
2017

Variations for Myositis

Expression for Myositis

Search GEO for disease gene expression data for Myositis.

Pathways for Myositis

Pathways related to Myositis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.5 AARS HARS NARS TARS
2 10.45 APP BACE1 BACE2

GO Terms for Myositis

Cellular components related to Myositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.96 AARS APP DYSF FBL MB NARS
2 cell surface GO:0009986 9.72 APP BACE1 BACE2 DMD NCAM1
3 Z disc GO:0030018 9.54 CAPN3 DMD TTN
4 cytosol GO:0005829 9.5 AARS APP CAPN3 CHKB DMD GNE
5 astrocyte projection GO:0097449 9.16 APP DMD
6 myofibril GO:0030016 9.13 CAPN3 DMD MYOD1

Biological processes related to Myositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 translation GO:0006412 9.76 AARS HARS NARS TARS
2 skeletal muscle tissue regeneration GO:0043403 9.48 DMD MSTN
3 muscle organ development GO:0007517 9.46 CAPN3 DMD MSTN MYOD1
4 response to muscle activity GO:0014850 9.43 CAPN3 MSTN
5 tRNA aminoacylation GO:0043039 9.4 AARS TARS
6 amyloid-beta metabolic process GO:0050435 9.37 BACE1 BACE2
7 negative regulation of myoblast proliferation GO:2000818 9.32 MSTN MYOD1
8 myotube cell development GO:0014904 9.26 DMD MYOD1
9 muscle cell cellular homeostasis GO:0046716 9.13 CAPN3 DMD MSTN
10 tRNA aminoacylation for protein translation GO:0006418 8.92 AARS HARS NARS TARS

Molecular functions related to Myositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.61 AARS CHKB GNE HARS IFIH1 NARS
2 ligase activity GO:0016874 9.56 AARS HARS NARS TARS
3 structural constituent of muscle GO:0008307 9.33 CAPN3 DMD TTN
4 aminoacyl-tRNA ligase activity GO:0004812 8.92 AARS HARS NARS TARS

Sources for Myositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....